Dr Katrina Pollock
MA MBBS MRCP DipGUM DipHIV DFSRH PhD
MRC Clinician Scientist in Vaccinology
- Chief investigator for the Lymph nodE single-cell Genomics AnCestrY and ageing (LEGACY) Network
- Chief and principal investigator for experimental medicine and first-in-human vaccine studies
- Honorary consultant in sexual health.
Human tissue based vaccine immunology.
Dr Katrina Pollock is an MRC Clinician Scientist in Vaccinology at the Oxford Vaccine Group, University of Oxford, Honorary Clinical Senior Lecturer in Vaccinology at the Department of Infectious Disease, Imperial College London, and Honorary Consultant in Sexual Health. She read medicine as an undergraduate at Newnham College, University of Cambridge, and Imperial College London before completing specialty training as a clinician scientist in genitourinary and HIV medicine, with a PhD and lectureship in immunology. Having led a series of first-in-human trials of novel vaccines including COVID-19 at Imperial College London, she received an award for substantial and exceptional achievement during the COVID-19 pandemic. Her work seeks to define tissue-based mechanisms of vaccine immunogenicity in diverse populations to leverage this for novel vaccine design. She is passionate about involving the public and participants at all stages, to lead innovative research that changes lives for the better.
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Liu Z. et al, (2023), eClinicalMedicine, 64
Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.
Khan M. et al, (2023), Open Forum Infect Dis, 10
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators None. et al, (2023), JAMA, 329, 1183 - 1196
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Szubert AJ. et al, (2023), eClinicalMedicine, 56
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3